ASCO GI 2021 | Pembrolizumab vs. chemo in first-line mCRC

Thierry André, MD, Hospital Saint Antoine, Paris, France, provides an update on the results of the KEYNOTE-177 study (NCT02563002), a Phase III trial evaluating the activity of pembrolizumab versus chemotherapy as a first-line approach for patients with microsatellite-instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).